Apyx Medical (NASDAQ:APYX) Upgraded to “Strong-Buy” at Roth Capital

Roth Capital upgraded shares of Apyx Medical (NASDAQ:APYX) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other brokerages have also weighed in on APYX. Citizens Jmp raised shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective on the stock in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Apyx Medical in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Apyx Medical currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Apyx Medical Price Performance

Shares of NASDAQ:APYX opened at $3.72 on Monday. The company has a current ratio of 4.44, a quick ratio of 3.61 and a debt-to-equity ratio of 5.69. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $4.44. The business has a fifty day simple moving average of $3.59 and a 200 day simple moving average of $2.61. The firm has a market cap of $142.25 million, a price-to-earnings ratio of -10.33 and a beta of 1.49.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Thursday, November 6th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%.The firm had revenue of $12.88 million for the quarter, compared to the consensus estimate of $12.00 million. As a group, sell-side analysts predict that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of APYX. Citadel Advisors LLC acquired a new position in Apyx Medical during the 3rd quarter valued at $28,000. Fisher Asset Management LLC acquired a new position in shares of Apyx Medical in the second quarter valued at $34,000. Caprock Group LLC bought a new position in Apyx Medical in the third quarter worth $40,000. Osaic Holdings Inc. bought a new position in Apyx Medical in the second quarter worth $50,000. Finally, Franklin Resources Inc. acquired a new stake in Apyx Medical during the third quarter worth $59,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.